REGN5458

Overview

REGN5458 is a bispecific BCMA/CD3 T cell engaging antibody.

SparkCures ID 351
Developed By Regeneron Pharmaceuticals
Generic Name REGN5458
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
View Trial
Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

December 08, 2019

Results were presented today at the American Society of Hematology (ASH) Annual Meeting from the first two dose groups (3 mg and 6 mg weekly doses).

  • Patients had a median of seven lines of prior systemic therapy, and all had failed CD38 antibody treatment.
  • Responses were observed in 4 of 7 (57%) patients, including 3 of 4 (75%) in the 6 mg dose group.
  • In the 6 mg dose group, 2 patients (50%) were also minimal residual disease (MRD) negative, meaning that no cancer cells were detectable in their bone marrow.
Read More

Resources